Xenetic Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary
14/05/2025 19:15
Xenetic Biosciences Inc XBIO.OQ reported a quarterly adjusted loss of 59 cents per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -78 cents. The lone analyst forecast for the quarter was for a loss of 72 cents per share. Revenue rose 16.1% to $593.26 thousand from a year ago; analysts expected $670.00 thousand. Xenetic Biosciences Inc's reported EPS for the quarter was a loss of 59 cents. The company reported a quarterly loss of $903.14 thousand. Xenetic Biosciences Inc shares had risen by 17.2% this quarter and lost 23.3% so far this year. FORECAST CHANGES In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "hold" This summary was machine generated from LSEG data May 14 at 06:15 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Mar. 31 2025 | -0.72 | -0.59 | Beat |
| Dec. 31 2024 | -0.20 | -0.68 | Missed |
| Sep. 30 2024 | -0.14 | -0.28 | Missed |
| Jun. 30 2024 | -0.83 | -0.83 | Met |